Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2010 Results, and Host Conference Call on March 16, 2011

Mar 09, 2011, 08:02 ET from Transcept Pharmaceuticals, Inc.

POINT RICHMOND, Calif., March 9, 2011 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Wednesday, March 16, 2011 at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2010 financial results.  The conference call will follow the release of the Transcept fourth quarter and full year 2010 financial results after the close of market that day.

Conference Call Information

         Date: Wednesday, March 16, 2011

         Time: 4:30 p.m. EDT

         Dial-in (U.S.): 877-638-4558

         Dial-in (International): 914-495-8537

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call through May 31, 2011.

A telephone replay of the conference call will be available shortly after the conclusion of the call through March 23, 2011.  The replay telephone number is 800-642-1687 (U.S.) or 706-645-9291 (International), replay passcode: 49092674.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet). Transcept has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) that seeks approval of Intermezzo® as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The FDA has assigned a date of July 14, 2011 for its completion of the Intermezzo® NDA review. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. Transcept is also developing TO-2061, a low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with approved first-line pharmacotherapy. For further information, please visit the Transcept website at: www.transcept.com.

Contact:

Transcept Pharmaceuticals, Inc.

Greg Mann

Director, Corporate Communications

(510) 215-3567

gmann@transcept.com

SOURCE Transcept Pharmaceuticals, Inc.



RELATED LINKS

http://www.transcept.com